Kyntra Bio Inc (KYNB)

$7.37 +0.29 (4.10%)
Market Cap 29.02M
Revenue (ttm) 6.44M
Net Income (ttm) 183.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 2,848.60%
Debt to Equity Ratio 0.00
Volume 12,300
Avg Vol 35,882
Day's Range N/A - N/A
Shares Out 4.05M
Stochastic %K 61%
Beta 0.90
Analysts Sell
Price Target $43.00

Company Profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 100 #6009, San Francisco, United States
Latest News on KYNB
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 4:05 PM EDT - 6 days ago

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 16, 2026, 4:02 PM EDT - 4 weeks ago

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026, 7:00 AM EDT - 5 weeks ago

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

What's Going On With Kyntra Bio Stock Tuesday?

Feb 24, 2026, 8:27 AM EST - 7 weeks ago

What's Going On With Kyntra Bio Stock Tuesday?

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

Feb 23, 2026, 5:10 PM EST - 7 weeks ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

Kyntra Bio to Participate in Upcoming Investor Conferences

Feb 17, 2026, 4:05 PM EST - 2 months ago

Kyntra Bio to Participate in Upcoming Investor Conferences

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Jan 7, 2026, 7:30 AM EST - 3 months ago

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

FibroGen to Report Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 5 months ago

FibroGen to Report Third Quarter 2025 Financial Results

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Sep 24, 2025, 7:00 AM EDT - 7 months ago

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 4:02 PM EDT - 8 months ago

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 18, 2025, 7:00 AM EDT - 8 months ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:02 PM EDT - 8 months ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

FibroGen to Report Second Quarter 2025 Financial Results

Aug 4, 2025, 4:02 PM EDT - 9 months ago

FibroGen to Report Second Quarter 2025 Financial Results

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 13, 2025, 8:22 AM EDT - 10 months ago

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ADBE

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 12, 2025, 4:02 PM EDT - 10 months ago

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

Jun 9, 2025, 4:02 PM EDT - 11 months ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 8, 2025, 4:24 AM EDT - 1 year ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

FibroGen to Report First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Report First Quarter 2025 Financial Results

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

Feb 20, 2025, 1:08 PM EST - 1 year ago

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

AZN

FibroGen sells China unit to AstraZeneca in deal worth $160 million

Feb 20, 2025, 6:40 AM EST - 1 year ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Feb 20, 2025, 6:30 AM EST - 1 year ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

FibroGen Appoints David DeLucia as Chief Financial Officer

Dec 16, 2024, 8:05 AM EST - 1 year ago

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

Jul 31, 2024, 12:33 PM EDT - 1 year ago

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

FibroGen to Report Second Quarter 2024 Financial Results

Jul 30, 2024, 4:07 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2024 Financial Results

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:05 PM EDT - 2 years ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Jun 3, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 23, 2024, 5:05 PM EDT - 2 years ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

FibroGen to Participate in Upcoming Investor Conferences

May 7, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Participate in Upcoming Investor Conferences

FibroGen Reports First Quarter 2024 Financial Results

May 6, 2024, 4:02 PM EDT - 2 years ago

FibroGen Reports First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Report First Quarter 2024 Financial Results

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 24, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Apr 2, 2024, 5:46 PM EDT - 2 years ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Mar 11, 2024, 7:00 AM EDT - 2 years ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

FibroGen regains rights to anemia drug from AstraZeneca

Feb 26, 2024, 4:18 PM EST - 2 years ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:06 PM EST - 2 years ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 26, 2024, 4:05 PM EST - 2 years ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 7:00 AM EST - 2 years ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Feb 5, 2024, 7:00 AM EST - 2 years ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Jan 25, 2024, 7:00 AM EST - 2 years ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Dec 9, 2023, 5:02 PM EST - 2 years ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

FibroGen Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 4:01 PM EST - 2 years ago

FibroGen Reports Third Quarter 2023 Financial Results

FibroGen to Report Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 2 years ago

FibroGen to Report Third Quarter 2023 Financial Results